Brand Name: Lorbrena
Generic Name: lorlatinib
Drug Class: Antineoplastics, Anaplastic Lymphoma Kinase Inhibitors
What is Lorbrena, and what is it used for?
Lorbrena (lorlatinib) is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC)
- that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene and,
- that has spread to other parts of your body and,
- who have taken the medicine alectinib or ceritinib or who have taken both the medicine crizotinib and at least 1 other medicine to treat NSCLC that is caused by the ALK gene, and
- their NSCLC is no longer responding to these treatments. It is not known if Lorbrena is safe and effective in children.
What are the side effects of Lorbrena?
The most common side effects of Lorbrena include:
- swelling in your arms, legs, hands and feet (edema)
- numbness and tingling feeling in your joints or arms and legs (peripheral neuropathy)
- difficulty thinking or confusion
- difficulty breathing
- tiredness (fatigue)
- weight gain
- pain in your joints
- changes in mood, feeling sad or anxious
Lorbrena may cause decreased fertility in males. In males, this could affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.
These are not all of the possible side effects of Lorbrena. For more information, ask your healthcare provider or pharmacist.
Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is the dosage for Lorbrena?
- Select patients for the treatment of metastatic NSCLC with Lorbrena based on the presence of ALK positivity in tumor specimens.
- Information on FDA-approved tests for the detection of ALK rearrangements in NSCLC is available at http://www.fda.gov/CompanionDiagnostics.
- The recommended dosage of Lorbrena is 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
- Swallow tablets whole. Do not chew, crush or split tablets. Do not ingest if tablets are broken, cracked, or otherwise not intact.
- Take Lorbrena at the same time each day. If a dose is missed, then take the missed dose unless the next dose is due within 4 hours. Do not take 2 doses at the same time to make up for a missed dose.
- Do not take an additional dose if vomiting occurs after Lorbrena but continue with the next scheduled dose.
Dosage Modifications for Adverse Reactions
The recommended dose reductions are:
- First dose reduction: Lorbrena 75 mg orally once daily
- Second dose reduction: Lorbrena 50 mg orally once daily
Permanently discontinue Lorbrena in patients who are unable to tolerate 50 mg orally once daily.
Dosage modifications for adverse reactions of Lorbrena are provided in Table 1.
Table 1 : Recommended Lorbrena Dosage Modifications for Adverse Reactions
|Adverse Reactiona||Dosage Modifications|
|Central Nervous System Effects|
|Grade 1||Continue at the same dose or withhold the dose until recovery to baseline. Resume Lorbrena at the same dose or at a reduced dose.|
|Grade 2 OR Grade 3||Withhold dose until Grade 0 or 1. Resume Lorbrena at a reduced dose.|
|Grade 4||Permanently discontinue Lorbrena.|
|Grade 4 hypercholesterolemia OR Grade 4 hypertriglyceridemia||Withhold Lorbrena until recovery of hypercholesterolemia and/or hypertriglyceridemia to less than or equal to Grade 2. Resume Lorbrena at the same dose. If severe hypercholesterolemia and/or hypertriglyceridemia recurs, resume Lorbrena at a reduced dose.|
|Atrioventricular (AV) Block|
|Second-degree AV block||Withhold Lorbrena until PR interval is less than 200 ms. Resume Lorbrena at a reduced dose.|
|First occurrence of complete AV block||Withhold Lorbrena until
If no pacemaker is placed, resume Lorbrena at a reduced dose.
|Recurrent complete AV block||Place pacemaker or permanently discontinue Lorbrena.|
|Interstitial Lung Disease (ILD)/Pneumonitis|
|Any Grade treatment-related ILD/Pneumoniti s||Permanently discontinue Lorbrena.|
|Grade 3 (SBP greater than or equal to 160 mmHg or DBP greater than or equal to 100 mmHg; medical intervention indicated; more than one antihypertensive drug, or more intensive therapy than previously used indicated)||Withhold Lorbrena until hypertension has recovered to Grade 1 or less (SBP less than 140 mmHg and DBP less than 90 mmHg), then resume Lorbrena at the same dose. If Grade 3 hypertension recurs, withhold Lorbrena until recovery to Grade 1 or less, and resume at a reduced dose. If adequate hypertension control cannot be achieved with optimal medical management, permanently discontinue Lorbrena.|
|Grade 4 (life-threatening consequences, urgent intervention indicated)||Withhold Lorbrena until recovery to Grade 1 or less, and resume at a reduced dose or permanently discontinue Lorbrena. If Grade 4 hypertension recurs, permanently discontinue Lorbrena.|
|Grade 3 ((greater than 250 mg/dL) despite optimal anti-hyperglycemic therapy OR Grade 4||Withhold Lorbrena until hyperglycemia is adequately controlled, then resume Lorbrena at the next lower dosage. If adequate hyperglycemic control cannot be achieved with optimal medical management, permanently discontinue Lorbrena.|
|Other Adverse Reactions|
|Grade 1 OR Grade 2||Continue Lorbrena at same dose or reduced dose.|
|Grade 3 OR Grade 4||Withhold Lorbrena until symptoms resolve to less than or equal to Grade 2 or baseline. Resume Lorbrena at reduced dose.|
|Abbreviation: AV=atrioventricular; DBP=diastolic blood pressure; SBP=systolic blood pressure.
a Grade based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Concomitant Use of Strong CYP3A Inducers
- Lorbrena is contraindicated in patients taking strong CYP3A inducers. Discontinue strong CYP3A inducers for 3 plasma half-lives of the strong CYP3A inducer prior to initiating Lorbrena.
Concomitant Use of Moderate CYP3A Inducers
- Avoid concomitant use of moderate CYP3A inducers with Lorbrena. If concomitant use with moderate CYP3A inducers is unavoidable, increase the Lorbrena dose to 125 mg once daily.
Dosage Modification for Strong CYP3A Inhibitors
- Avoid concomitant use of Lorbrena with strong CYP3A inhibitors. If concomitant use with a strong CYP3A inhibitor is unavoidable, reduce the starting dose of Lorbrena from 100 mg orally once daily to 75 mg orally once daily.
- In patients who have had a dose reduction to 75 mg orally once daily due to adverse reactions and who initiate a strong CYP3A inhibitor, reduce the Lorbrena dose to 50 mg orally once daily.
- If concomitant use of a strong CYP3A inhibitor is discontinued, increase the Lorbrena dose (after 3 plasma half-lives of the strong CYP3A inhibitor) to the dose that was used before starting the strong inhibitor.
Dosage Modification for Fluconazole
- Avoid concomitant use of Lorbrena with fluconazole. If concomitant use is unavoidable, reduce the starting dose of Lorbrena from 100 mg orally once daily to 75 mg orally once daily.
Dosage Modification for Severe Renal Impairment
- Reduce the recommended dosage of Lorbrena for patients with severe renal impairment (creatinine clearance [CLcr] 15 to < 30 mL/min, estimated by Cockcroft-Gault) from 100 mg to 75 mg orally once daily.
What drugs interact with Lorbrena?
Effect of Other Drugs on Lorbrena
Strong CYP3A Inducers
- Concomitant use of Lorbrena with a strong CYP3A inducer decreased lorlatinib plasma concentrations, which may decrease the efficacy of Lorbrena.
- Severe hepatotoxicity occurred in healthy subjects receiving Lorbrena with rifampin, a strong CYP3A inducer. In 12 healthy subjects receiving a single 100 mg dose of Lorbrena with multiple daily doses of rifampin, Grade 3 or 4 increases in ALT or AST occurred in 83% of subjects and Grade 2 increases in ALT or AST occurred in 8%. A possible mechanism for hepatotoxicity is through activation of the pregnane X receptor (PXR) by Lorbrena and rifampin, which are both PXR agonists.
- Lorbrena is contraindicated in patients taking strong CYP3A inducers. Discontinue strong CYP3A inducers for 3 plasma half-lives of the strong CYP3A inducer prior to initiating Lorbrena.
Moderate CYP3A Inducers
- Concomitant use of Lorbrena with a moderate CYP3A inducer decreased lorlatinib plasma concentrations, which may decrease the efficacy of Lorbrena.
- Avoid concomitant use of moderate CYP3A inducers with Lorbrena. If concomitant use is unavoidable, increase the Lorbrena dose.
Strong CYP3A Inhibitors
- Concomitant use with a strong CYP3A inhibitor increased lorlatinib plasma concentrations, which may increase the incidence and severity of adverse reactions of Lorbrena. Avoid concomitant use of Lorbrena with a strong CYP3A inhibitor. If concomitant use cannot be avoided, reduce the Lorbrena dosage.
- Concomitant use of Lorbrena with fluconazole may increase lorlatinib plasma concentrations, which may increase the incidence and severity of adverse reactions of Lorbrena. Avoid concomitant use of Lorbrena with fluconazole. If concomitant use cannot be avoided, reduce the Lorbrena dosage.
Effect of Lorbrena on Other Drugs
Certain CYP3A Substrates
- Lorbrena is a moderate CYP3A inducer. Concomitant use of Lorbrena decreases the concentration of CYP3A substrates, which may reduce the efficacy of these substrates.
- Avoid concomitant use of Lorbrena with certain CYP3A substrates, for which minimal concentration changes may lead to serious therapeutic failures. If concomitant use is unavoidable, increase the CYP3A substrate dosage in accordance with approved product labeling.
Certain P-glycoprotein (P-gp) Substrates
- Lorbrena is a moderate P-gp inducer. Concomitant use of Lorbrena decreases the concentration of P-gp substrates, which may reduce the efficacy of these substrates.
- Avoid concomitant use of Lorbrena with certain P-gp substrates for which minimal concentration changes may lead to serious therapeutic failures.
- If concomitant use is unavoidable, increase the P-gp substrate dosage in accordance with approved product labeling.
Pregnancy and breastfeeding
- There are no available data on Lorbrena use in pregnant women.
- There are no data on the presence of lorlatinib or its metabolites in either human or animal milk or its effects on the breastfed infant or on milk production.
- Because of the potential for serious adverse reactions in breastfed infants, instruct women not to breastfeed during treatment with Lorbrena and for 7 days after the final dose.
Lorbrena is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC). The most common side effects of Lorbrena include swelling in your arms, legs, hands and feet (edema), numbness and tingling feeling in your joints or arms and legs (peripheral neuropathy), difficulty thinking or confusion, difficulty breathing, tiredness (fatigue), weight gain, pain in your joints, changes in mood, feeling sad or anxious, and diarrhea.
Multimedia: Slideshows, Images & Quizzes
Lung Cancer: Early Signs, Symptoms, Stages
Learn about lung cancer early warning signs, symptoms and treatments. What causes stage IV lung cancer? Get more information on...
Lung Cancer Quiz: Signs and Symptoms
Lung cancer is the number one cause of cancer deaths in both men and women in the U.S. and worldwide. Get the facts about lung...
Picture of Lung Cancer
Cancer of the lung, like all cancers, results from an abnormality in the body's basic unit of life, the cell. See a picture of...
Lung Cancer Risks: Myths and Facts
Learn about lung cancer myths and facts. Explore how cigar smoke, menthol, and pollution can increase your risk of lung cancer...
Global Warning: 10 Ways Climate Change Increases Rates of Lung Cancer
Find out how climate change is contributing to lung cancer around the world.
Related Disease Conditions
Lung cancer kills more men and women than any other form of cancer. Eight out of 10 lung cancers are due to tobacco smoke. Lung cancers are classified as either small-cell or non-small-cell lung cancers.
What Should I Do After an Unwanted Pregnancy?
There are a variety of options that may help you handle your situation. It might help you to visualize each option and decide how you feel about it. Consider reaching out to trained professionals or close friends if you get overwhelmed.
What Percentage of Smokers Get Lung Cancer?
According to the Centers for Disease Control and Prevention (CDC), lung cancer develops in around 10 to 20 percent of all smokers. Scientists believe that smoking is responsible for over 80 percent of lung cancers.
Can You Survive Metastatic Lung Cancer?
Once cancer spreads to other parts of the body (metastasis), it is much harder to treat, which means metastatic lung cancer typically has a five-year survival rate of seven percent.
Can Pancoast Lung Cancer Be Cured?
Pancoast tumors are a rare type of lung cancer that forms at the extreme top of either of the lungs. Due to their location at the top of the lung, there’s a high chance that cancer might attack the adjacent tissue and produce typical symptoms.
Can You Survive ALK Lung Cancer?
Generally, survival rates for ALK-positive lung cancer are better than those of non-small cell lung cancer overall. Furthermore, people with advanced ALK-positive lung cancer usually live for an average of seven years after diagnosis.
Pancoast Tumor (Lung Cancer)
Pancoast tumors are lung cancers that form at the top of the lung. They tend to spread to the chest wall rather than the lung tissue. These tumors usually respond well to treatment as long as they don't spread or metastasize, to the lymph nodes or other systems.
What Are Strange Signs of Lung Cancer?
Sometimes lung cancer causes surprising symptoms that do not appear to be related to the lungs. Here are 17 strange signs of lung cancer to look out for.
Can You Smoke When You Have Lung Cancer?
Continuing to smoke after the diagnosis or during the treatment of lung cancer is usually not recommended because it may decrease the survival rate and even interfere with the treatment process.
How Long Can You Live With Stage IV Lung Cancer?
While stage IV lung cancer is hard to cure, advancements in cancer treatments may help improve your lifespan and survival rate, depending on your overall state of health.
Small Cell Lung Cancer vs. Non-Small Cell Lung Cancer
Non-small cell lung cancers (NSCLC) consist of large cell carcinomas, adenocarcinomas, and squamous cell carcinomas. Small cell lung cancer (SCLC) usually starts in the bronchi and typically appears in those who smoke. SCLC and NSCLC are staged in different manners, and SCLC tends to metastasize more quickly than NSCLC. Signs and symptoms of NSCLC and SCLC include shortness of breath, coughing up blood, recurring lung infections, and chest pain. Treatment may involve radiation therapy, chemotherapy, and surgery.
What Is the Survival Rate for Stage I Lung Cancer?
Typically, the survival rate for stage I lung cancer is anywhere from 70 to 92 percent, depending on the type. Early diagnosis and treatment can improve the outlook.
How Long Will You Live With Stage III Lung Cancer?
The lifespan and survival rate of patients diagnosed with stage III lung cancer depends on the type and subtype of the cancerous tumor.
How Do You Test Yourself for Lung Cancer?
Lung cancer is the second leading cause of death in the United States. It is hard to detect in the early stages because it does not cause obvious signs and symptoms. Signs and symptoms most often appear when lung cancer has grown deep and extensively inside the lung tissue and/or spread to other organs.
What Are the Four Types of Lung Cancer?
The four types of lung cancer are classified by what kind of cells the cancer affects and what the tumor cells look like under a microscope. Lung cancers can be small-cell or non-small cell, further classified as squamous cell carcinoma or adenocarcinoma.
What Is Lung Cancer Pain Like?
Lung cancer, also known as lung carcinoma, is defined as an uncontrolled growth of tumor cells in the lungs. The principal role of the lungs is to allow gaseous exchange between the air and blood and facilitate the availability of oxygen for cellular functions.
What Does Lung Cancer Feel Like When It Starts?
Lung cancer refers to the uncontrolled growth of cells that starts in the lungs. Lung cancer occurs when any of the several cells in the lungs undergo an abnormal change in its genetic code. This change is called a mutation.
How Aggressive Is Non-Small Cell Lung Cancer?
NSCLC is slow-growing and less aggressive than SCLC, which means the survival rate and lifespan are better compared to other types of lung cancer.
What Is the Survival Rate of Non-Small Cell Lung Cancer?
There are two main types of lung cancers, namely, small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC accounts for 85% of all lung cancer cases in the United States. It must be noted that medical science is progressing with leaps and bounds, and treatment for lung cancer must be initiated and maintained despite the stage of diagnosis.
Is There a Screening Test for Lung Cancer?
A screening test is generally performed as a preventative measure to detect a potential health problem or disease in a person who is yet to have signs or symptoms. There is a screening test for lung cancer, however it is only deemed necessary for people at risk for lung cancer.
Where Do You Feel Lung Cancer Pain?
In its early stages, lung cancer typically does not produce any signs and symptoms. However, if it does, you will experience coughing and wheezing that do not go away within three weeks.
How Does Smoking Affect Lung Cancer?
Tobacco smoke is a complex mixture of gaseous and particulate substances, and many of these are potential carcinogens. More than 4000 individual components have been identified in cigarette smoke. Some of these are carcinogens (substances that contribute to the development of cancer), such as benzene and nitrosamines.
What Are The Main Causes Of Lung Cancer?
Lung cancer refers to an uncontrolled growth of cells that starts in the lungs. The cells then cluster together to form a tumor that can spread to other sites in the body. Lung cancer is the third most common cancer in the United States (skin cancer being the first and prostate and breast cancer being the second most common cancer in men and women, respectively).
Six Early Signs of Lung Cancer
Lung cancer is the third most common cancer in the United States. It may not show its signs and symptoms in its early stages. Signs and symptoms typically appear in the advanced stage of the disease.
Can Lung Cancer Go Away?
Lung cancer can go away if treated in the early stages, especially when the cancer is localized and has not spread to nearby lymph nodes or other sites in the body.
Treatment & Diagnosis
- Lung Cancer FAQs
- Sensitive to Smoke, Lung Cancer Gene
- Lung Cancer and Chemotherapy
- Lung Cancer Signs and Symptoms
- 5 Causes of Lung Cancer in Non-Smokers
- Dana Reeve Dies of Lung Cancer by Dr. Stoppler
- What Is the Survival Rate for Lung Cancer Nodules?
- Why Does Lung Cancer Spread So Fast?
- Can You Get Lung Cancer After Quitting Smoking?
- Stage IV Lung Cancer With ALK (Anaplastic Lymphoma Kinase) Rearrangement
Medications & Supplements
Prevention & Wellness
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.